Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 24, 2012

View Archived Issues

Study reveals new therapeutic use for phosphodiesterase 5 inhibitors

Revalesio set to launch new trial of nebulized asthma combination therapy

SK Biopharmaceuticals begin U.S. phase II trial of SKL-11197

HER2 gene imaging analysis system receives FDA clearance

New hepatocyte growth factor receptor inhibitor advances to clinic

Daiichi Sankyo reviews pipeline progress

Japanese researchers design novel agents for neuropathic pain

Bristol-Myers Squibb presents new anticancer agents

Roche offers overview of 2011

Novel cannabinoid receptor agonists disclosed by Astellas Pharma

Corning presents novel compounds for GPR35 receptor-related disorders

Spanish scientists patent new protein kinase inhibitors

First visceral leishmaniasis vaccine enters clinical testing

Novel agents for pain prepared by Nutek Pharma

New system allows creation and screening of macrocyclic N-methylated peptide libraries

PDUFA date set for Impax Pharmaceuticals' IPX-066 NDA

VX-222 combination therapy shows promise in hepatitis C

New therapeutic target identified for hepatitis C

FDA committee votes on aclidinium bromide NDA

Can-Fite BioPharma product obtains FDA orphan drug status

Cedars-Sinai receives grant for Alzheimer's research

ULURU's Altrazeal obtains approval in Australia

Omeros unlocks new class A orphan GPCRs

EMA grants new marketing approval for dry powder inhaler

EMA accepts Genzyme's teriflunomide MAA

Dosing begins in phase I Vasomera trial

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026